Ukulethwa kwezidakamizwa okuhlosiwe ezibhedlela umdlavuza

Ukulethwa kwezidakamizwa okuhlosiwe ezibhedlela umdlavuza: Ukuthuthukisa ukwelashwa kwe-Effessicytartartargegegegegegegegegegegegeged systems izinhlelo zomdlavuza, okunikeza ukusebenza kahle kwemiphumela emibi yeziguli. Lo mbhalo uhlola izindlela ezahlukahlukene ezisetshenziswe Ukulethwa kwezidakamizwa okuhlosiwe ezibhedlela umdlavuza, ukuhlola izindlela zabo, izinzuzo, nezinselelo. Sizokwakha izibonelo ezithile futhi sibheke ikusasa lale nkambu elibalulekile e-Oncology.

Ukuqonda ukulethwa kwezidakamizwa okuhlosiwe

Kuyini ukulethwa kwezidakamizwa okuhlosiwe?

Ngokungafani nendabuko ye-chemotherapy, eyisabalalisa izidakamizwa emzimbeni wonke, Ukulethwa kwezidakamizwa okuhlosiwe ezibhedlela umdlavuza Igxile ekuletheni abenzeli bezokwelapha ngqo kumaseli womdlavuza. Le ndlela inciphisa ukulimala kwezicubu ezinempilo, okuholela emiphumeleni emibi embalwa kanye nemiphumela yokwelashwa ethuthukisiwe. Izindlela ezahlukahlukene ziqashwa ukufeza lokhu kuhanjiswa okuhlosiwe, ngalinye linezimpawu ezihlukile nezinhlelo zokusebenza.

Izindlela zokulethwa kwezidakamizwa okuhlosiwe

Izindlela eziningana zisiza Ukulethwa kwezidakamizwa okuhlosiwe ezibhedlela umdlavuza. Lokhu kufaka phakathi:

• I-Antibody-Drug Compionsetes (ADCS): Amasosha omzimba abopha ngokuqondile kumaseli womdlavuza, ephethe umuthi onamathiselwe ngqo esimindeni.
• Ukulethwa kwezidakamizwa kwe-Liposomal: Izidakamizwa zifakwe ngaphakathi kwama-liposomes, azobhekiswa kumaseli womdlavuza asebenzisa ama-ligands noma ama-antibodies athile.
• Ukulethwa kwezidakamizwa kwe-nanoparticle: Ama-nanoparticles angenzelwe ukuthwala izidakamizwa kwisiza se-tumor, engase asebenzise umphumela wokuvuselelwa kanye nokugcinwa (esPr) umphumela.
• Ama-nanoparticles ahlosiwe: Lokhu kusetshenziswa ukuguqulwa komhlaba okufana nama-ligands noma ama-antibodies okuqondiswa okuthile kumaseli esimilani.

Izinhlobo zezinhlelo ezihlosiwe zokulethwa kwezidakamizwa

Izimbotshana zezidakamizwa ze-antibody-Drug (ADCs)

I-ADCS isibonelo esivelele se Ukulethwa kwezidakamizwa okuhlosiwe ezibhedlela umdlavuza. Bahlanganisa ukucaciswa kwama-antibodies e-monoclonal nge-potency yezidakamizwa ze-cytotoxic. Le ndlela ithuthukisa ukusebenza kahle ngokuletha ngqo umuthi kumaseli womdlavuza, ngenkathi isindisa izicubu ezinempilo. Isibonelo, i-Trastuzumab Emtansine (Kadcyla) iyi-ADC esetshenziselwa ukwelapha umdlavuza webele we-Hers2.¹

Ukulethwa kwezidakamizwa kwe-Liposomal

Ama-liposomes avumela umuthi, uyivikele ekujuleni nasekukhuliseni isikhathi sawo sokujikeleza kwegazi. Le pharmacokinetics ethuthukisiwe ivumela ukulethwa okuhlosiwe kumaseli esithibanisa ama-tumor ngokusebenzisa ama-ligands athile ahlosiwe noma ukunqwabelana okungeyona nge-EPR. I-Doxorubicin Liposomes (E.G., Doxil) isibonelo esivunyiwe emtholampilo.²

Izinzuzo nezinselelo zokulethwa kwezidakamizwa okuhlosiwe

Ikusasa lokulethwa kwezidakamizwa okuhlosiwe kwezibhedlela ezinomdlavuza

Ucwaningo luyaqhubeka nokuhlaziya nokwandisa amathuba we Ukulethwa kwezidakamizwa okuhlosiwe ezibhedlela umdlavuza. Intuthuko nge-nanotechnology, i-genomics, kanye nokucabanga kuholela ekuthuthukisweni kwezinhlelo eziyinkimbinkimbi futhi ezisebenzayo. Ukuhlanganiswa kwemithi eqondene nomuntu uqobo kanye nokusetshenziswa kwezindlela zokwelapha ezihlanganisiwe nakho kudlula indlela yemiphumela ethuthukisiwe ekwelashweni komdlavuza. Ngeminye imininingwane ngokwelashwa okuthuthukile komdlavuza kanye nocwaningo, vakashela I-Shandong Baafa Cancer Research Institute.

¹ I-FDA. (N.D.). I-Kadcyla (Trastuzumab Emtansine). Itholwe kusuka ku- https.gov/wrdsa.gov/drugs/informatemondrugs/frovevedrugs/ucm361642.htmiems.htks: //www.fda.gov.gov/rug

² I-FDA. (N.D.). Doxil (doxorubicicin hcl liposomal umjovo). Kubuyiselwe kusuka [https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=verview.process&papplno=020515] (https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=verview.process&papplno=020515)